JP2009532053A - インヴィヴォでの核酸配列のエピジェネティック修飾用組成物および方法 - Google Patents
インヴィヴォでの核酸配列のエピジェネティック修飾用組成物および方法 Download PDFInfo
- Publication number
- JP2009532053A JP2009532053A JP2009503661A JP2009503661A JP2009532053A JP 2009532053 A JP2009532053 A JP 2009532053A JP 2009503661 A JP2009503661 A JP 2009503661A JP 2009503661 A JP2009503661 A JP 2009503661A JP 2009532053 A JP2009532053 A JP 2009532053A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- sequence
- domain
- molecule
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical group 0.000 title claims description 39
- 238000000034 method Methods 0.000 title claims description 24
- 238000001727 in vivo Methods 0.000 title description 16
- 239000000203 mixture Substances 0.000 title description 9
- 230000004049 epigenetic modification Effects 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 66
- 201000011510 cancer Diseases 0.000 claims abstract description 55
- 230000017858 demethylation Effects 0.000 claims abstract description 54
- 238000010520 demethylation reaction Methods 0.000 claims abstract description 54
- 230000004568 DNA-binding Effects 0.000 claims abstract description 52
- 230000000694 effects Effects 0.000 claims abstract description 42
- 102100026846 Cytidine deaminase Human genes 0.000 claims abstract description 40
- 108010031325 Cytidine deaminase Proteins 0.000 claims abstract description 40
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 29
- 238000010374 somatic cell nuclear transfer Methods 0.000 claims abstract description 17
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 93
- 108090000623 proteins and genes Proteins 0.000 claims description 58
- 230000014509 gene expression Effects 0.000 claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 229920001184 polypeptide Polymers 0.000 claims description 33
- 239000013598 vector Substances 0.000 claims description 32
- 108020004414 DNA Proteins 0.000 claims description 29
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 230000001939 inductive effect Effects 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 19
- 230000009261 transgenic effect Effects 0.000 claims description 18
- 230000027455 binding Effects 0.000 claims description 16
- 230000001973 epigenetic effect Effects 0.000 claims description 16
- 210000001082 somatic cell Anatomy 0.000 claims description 16
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 230000001747 exhibiting effect Effects 0.000 claims description 9
- 239000013612 plasmid Substances 0.000 claims description 7
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- 230000005937 nuclear translocation Effects 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000001890 transfection Methods 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 108091026890 Coding region Proteins 0.000 claims description 3
- 108091092195 Intron Proteins 0.000 claims description 3
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims description 3
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims description 3
- 210000004507 artificial chromosome Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 239000003270 steroid hormone Substances 0.000 claims description 3
- 102000005969 steroid hormone receptors Human genes 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- 102000009331 Homeodomain Proteins Human genes 0.000 claims description 2
- 108010048671 Homeodomain Proteins Proteins 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 108700008625 Reporter Genes Proteins 0.000 claims description 2
- 108010085012 Steroid Receptors Proteins 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 15
- 230000011987 methylation Effects 0.000 description 23
- 238000007069 methylation reaction Methods 0.000 description 23
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 230000008775 paternal effect Effects 0.000 description 17
- 108700028369 Alleles Proteins 0.000 description 16
- 102100039556 Galectin-4 Human genes 0.000 description 15
- 108700019146 Transgenes Proteins 0.000 description 15
- 210000000130 stem cell Anatomy 0.000 description 15
- 230000007067 DNA methylation Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- 108010001515 Galectin 4 Proteins 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 13
- 102000037865 fusion proteins Human genes 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 108010066154 Nuclear Export Signals Proteins 0.000 description 10
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 10
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 10
- 229940104302 cytosine Drugs 0.000 description 10
- 230000009615 deamination Effects 0.000 description 10
- 238000006481 deamination reaction Methods 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000008774 maternal effect Effects 0.000 description 8
- 210000000287 oocyte Anatomy 0.000 description 8
- 230000008672 reprogramming Effects 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000033607 mismatch repair Effects 0.000 description 6
- 230000000392 somatic effect Effects 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 5
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102100027671 Transcriptional repressor CTCF Human genes 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102000012758 APOBEC-1 Deaminase Human genes 0.000 description 3
- 101150012656 APOBEC1 gene Proteins 0.000 description 3
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 101000782147 Homo sapiens WD repeat-containing protein 20 Proteins 0.000 description 3
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 3
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 3
- 102100036561 WD repeat-containing protein 20 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000001369 bisulfite sequencing Methods 0.000 description 3
- -1 cosmid Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000010228 ex vivo assay Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 2
- 230000035131 DNA demethylation Effects 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 101710096438 DNA-binding protein Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 2
- 101150002416 Igf2 gene Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 description 2
- 101710143275 Single-stranded DNA cytosine deaminase Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011254 conventional chemotherapy Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000008995 epigenetic change Effects 0.000 description 2
- 230000006846 excision repair Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000030147 nuclear export Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 102220281736 rs1555606104 Human genes 0.000 description 2
- 102200097257 rs199472847 Human genes 0.000 description 2
- 102220061201 rs786201790 Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 1
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000012666 Core Binding Factor Alpha 3 Subunit Human genes 0.000 description 1
- 108010079362 Core Binding Factor Alpha 3 Subunit Proteins 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 108020001738 DNA Glycosylase Proteins 0.000 description 1
- 102000028381 DNA glycosylase Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
- 108700034637 EC 3.2.-.- Proteins 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 102000017286 Histone H2A Human genes 0.000 description 1
- 108050005231 Histone H2A Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101150003028 Hprt1 gene Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000055601 Nanog Homeobox Human genes 0.000 description 1
- 108700026371 Nanog Homeobox Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000013406 biomanufacturing process Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000007247 enzymatic mechanism Effects 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010373 organism cloning Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000002660 stem cell treatment Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79027306P | 2006-04-07 | 2006-04-07 | |
| GBGB0607063.5A GB0607063D0 (en) | 2006-04-07 | 2006-04-07 | Compositions and methods for epigenetic modification of nucleic acid sequences in vivo |
| US79794206P | 2006-05-05 | 2006-05-05 | |
| GBGB0623644.2A GB0623644D0 (en) | 2006-04-07 | 2006-11-27 | Compositions and methods for epigenetic modification of nucleic acid sequences in vivo |
| PCT/GB2007/001304 WO2007128982A2 (en) | 2006-04-07 | 2007-04-10 | Compositions and methods for epigenetic modification of nucleic acid sequences in vivo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009532053A true JP2009532053A (ja) | 2009-09-10 |
| JP2009532053A5 JP2009532053A5 (enExample) | 2010-05-27 |
Family
ID=36539563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503661A Pending JP2009532053A (ja) | 2006-04-07 | 2007-04-10 | インヴィヴォでの核酸配列のエピジェネティック修飾用組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8298529B2 (enExample) |
| EP (1) | EP2010660B1 (enExample) |
| JP (1) | JP2009532053A (enExample) |
| GB (2) | GB0607063D0 (enExample) |
| WO (1) | WO2007128982A2 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020503040A (ja) * | 2016-12-28 | 2020-01-30 | トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． | 腫瘍溶解性ウイルスおよび治療用分子 |
| JP2020132584A (ja) * | 2019-02-21 | 2020-08-31 | 株式会社豊田中央研究所 | エピゲノム状態を制御する融合タンパク質及びその利用 |
| JP2021536229A (ja) * | 2018-08-23 | 2021-12-27 | サンガモ セラピューティクス， インコーポレイテッド | 操作された標的特異的な塩基エディター |
| JPWO2022244544A1 (enExample) * | 2021-05-20 | 2022-11-24 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2274430T3 (pl) * | 2008-04-30 | 2017-09-29 | Sanbio Inc | Komórki regenerujące nerwy ze zmianami w metylacji DNA |
| EP2128259A1 (en) | 2008-05-27 | 2009-12-02 | Koninklijke Philips Electronics N.V. | Therapy delivery and monitoring using a gene of interest-reporter fusion protein and optical imaging |
| DK2414507T3 (da) * | 2009-04-03 | 2014-08-25 | Medical Res Council | Mutanter af aktiveringsinduceret cytidin-deaminase (aid) og til anvendelsesfremgangsmåder |
| EP2258858A1 (en) * | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Transgenic LSD1 animal model for cancer |
| US20110104787A1 (en) * | 2009-11-05 | 2011-05-05 | President And Fellows Of Harvard College | Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences |
| US20130011380A1 (en) * | 2009-12-18 | 2013-01-10 | Blau Helen M | Use of Cytidine Deaminase-Related Agents to Promote Demethylation and Cell Reprogramming |
| EP3461896B1 (en) | 2011-07-15 | 2023-11-29 | The General Hospital Corporation | Methods of transcription activator like effector assembly |
| US9890364B2 (en) | 2012-05-29 | 2018-02-13 | The General Hospital Corporation | TAL-Tet1 fusion proteins and methods of use thereof |
| EP2906602B1 (en) | 2012-10-12 | 2019-01-16 | The General Hospital Corporation | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins |
| US10676749B2 (en) | 2013-02-07 | 2020-06-09 | The General Hospital Corporation | Tale transcriptional activators |
| US9721248B2 (en) | 2014-03-04 | 2017-08-01 | Bank Of America Corporation | ATM token cash withdrawal |
| GB201418965D0 (enExample) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| US10460367B2 (en) | 2016-04-29 | 2019-10-29 | Bank Of America Corporation | System for user authentication based on linking a randomly generated number to the user and a physical item |
| US10268635B2 (en) | 2016-06-17 | 2019-04-23 | Bank Of America Corporation | System for data rotation through tokenization |
| CN112334577B (zh) | 2018-04-19 | 2023-10-17 | 加利福尼亚大学董事会 | 用于基因编辑的组合物和方法 |
| US11680109B2 (en) | 2019-05-29 | 2023-06-20 | Duke University | Compositions and methods for detection and measurement of RNA modifications through targeted RNA editing |
| CN113383749B (zh) * | 2020-03-12 | 2025-11-18 | 中国医学科学院基础医学研究所 | 一种使用单个肿瘤细胞构建小鼠肿瘤模型的方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002534104A (ja) * | 1999-01-12 | 2002-10-15 | サンガモ バイオサイエンシーズ， インコーポレイテッド | ジンクフィンガータンパク質を用いた、細胞における、内因性遺伝子発現の調節 |
| JP2003527943A (ja) * | 2000-03-29 | 2003-09-24 | エイエム アセット マネジメント ピィティワイ リミテッド | ゴルフボールをクリーニングするための装置および方法 |
| WO2004106550A2 (en) * | 2003-06-02 | 2004-12-09 | The Babraham Institute | Identification and/or analysis of nucleic acids and/or proteins associated with a chromosome location |
| JP2004537260A (ja) * | 2000-12-07 | 2004-12-16 | サンガモ バイオサイエンシーズ， インコーポレイテッド | ジンクフィンガータンパク質による血管新生の調節 |
| WO2006030126A2 (fr) * | 2004-09-10 | 2006-03-23 | Institut Necker | Procédé pour l'accélération des mutations somatiques et son application en protéomique |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| ES2195196T3 (es) | 1996-12-30 | 2003-12-01 | Univ Johns Hopkins Med | Determinacion de la propensidad de un organo o un tejido al cancer por determinacion de su patron de impresion. |
| WO2000058480A1 (en) * | 1999-03-29 | 2000-10-05 | Kansai Technology Licensing Organization Co., Ltd. | Novel cytidine deaminase |
| AU5391401A (en) * | 2000-04-28 | 2001-11-12 | Sangamo Biosciences Inc | Targeted modification of chromatin structure |
| EP1303608A2 (en) | 2000-07-21 | 2003-04-23 | Syngenta Participations AG | Zinc finger domain recognition code and uses thereof |
| EP1418949B1 (en) * | 2001-07-31 | 2013-06-19 | THE STATE OF OREGON acting by and through THE STATE BOARD OF HIGHER EDUCATION on behalf of THE UNIVERSITY OF OREGON | Inhibitor of dna methylation |
| WO2003095636A2 (en) * | 2002-05-10 | 2003-11-20 | Medical Research Council | Activation induced deaminase (aid) |
-
2006
- 2006-04-07 GB GBGB0607063.5A patent/GB0607063D0/en not_active Ceased
- 2006-11-27 GB GBGB0623644.2A patent/GB0623644D0/en not_active Ceased
-
2007
- 2007-04-10 JP JP2009503661A patent/JP2009532053A/ja active Pending
- 2007-04-10 US US12/226,094 patent/US8298529B2/en not_active Expired - Fee Related
- 2007-04-10 EP EP07732348.3A patent/EP2010660B1/en not_active Not-in-force
- 2007-04-10 WO PCT/GB2007/001304 patent/WO2007128982A2/en not_active Ceased
-
2012
- 2012-10-05 US US13/646,008 patent/US8658393B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002534104A (ja) * | 1999-01-12 | 2002-10-15 | サンガモ バイオサイエンシーズ， インコーポレイテッド | ジンクフィンガータンパク質を用いた、細胞における、内因性遺伝子発現の調節 |
| JP2003527943A (ja) * | 2000-03-29 | 2003-09-24 | エイエム アセット マネジメント ピィティワイ リミテッド | ゴルフボールをクリーニングするための装置および方法 |
| JP2004537260A (ja) * | 2000-12-07 | 2004-12-16 | サンガモ バイオサイエンシーズ， インコーポレイテッド | ジンクフィンガータンパク質による血管新生の調節 |
| WO2004106550A2 (en) * | 2003-06-02 | 2004-12-09 | The Babraham Institute | Identification and/or analysis of nucleic acids and/or proteins associated with a chromosome location |
| WO2006030126A2 (fr) * | 2004-09-10 | 2006-03-23 | Institut Necker | Procédé pour l'accélération des mutations somatiques et son application en protéomique |
Non-Patent Citations (2)
| Title |
|---|
| JPN6012063342; Ｊ Ｂｉｏｌ Ｃｈｅｍ Ｖｏｌ．２７９ Ｎｏ．５０ Ｐａｇｅ．５２３５３-５２３６０ （２００４．１２．１０） * |
| JPN6012063344; Ｐｒｏｃ Ｎａｔｌ Ａｃａｄ Ｓｃｉ Ｕ Ｓ Ａ． ２００４ Ｆｅｂ １７；１０１（７）：１９７５-８０． * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020503040A (ja) * | 2016-12-28 | 2020-01-30 | トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． | 腫瘍溶解性ウイルスおよび治療用分子 |
| JP7110203B2 (ja) | 2016-12-28 | 2022-08-01 | トランジェーヌ | 腫瘍溶解性ウイルスおよび治療用分子 |
| JP2021536229A (ja) * | 2018-08-23 | 2021-12-27 | サンガモ セラピューティクス， インコーポレイテッド | 操作された標的特異的な塩基エディター |
| JP7541508B2 (ja) | 2018-08-23 | 2024-08-28 | サンガモ セラピューティクス， インコーポレイテッド | 操作された標的特異的な塩基エディター |
| JP2020132584A (ja) * | 2019-02-21 | 2020-08-31 | 株式会社豊田中央研究所 | エピゲノム状態を制御する融合タンパク質及びその利用 |
| JP7059965B2 (ja) | 2019-02-21 | 2022-04-26 | 株式会社豊田中央研究所 | エピゲノム状態を制御する融合タンパク質及びその利用 |
| US11479780B2 (en) | 2019-02-21 | 2022-10-25 | Kabushiki Kaisha Toyota Chuo Kenkyusho | Fusion protein for controlling epigenomic state, and use thereof |
| JPWO2022244544A1 (enExample) * | 2021-05-20 | 2022-11-24 | ||
| WO2022244544A1 (ja) * | 2021-05-20 | 2022-11-24 | 国立大学法人群馬大学 | エピゲノムが改変された動植物の親系統の製造に用いるための組成物およびその用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2010660A2 (en) | 2009-01-07 |
| US20130034881A1 (en) | 2013-02-07 |
| WO2007128982A2 (en) | 2007-11-15 |
| US8658393B2 (en) | 2014-02-25 |
| US20110138491A1 (en) | 2011-06-09 |
| US8298529B2 (en) | 2012-10-30 |
| GB0607063D0 (en) | 2006-05-17 |
| EP2010660B1 (en) | 2013-06-05 |
| WO2007128982A3 (en) | 2008-02-21 |
| GB0623644D0 (en) | 2007-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2010660B1 (en) | Compositions and methods for epigenetic modification of nucleic acid sequences in vivo | |
| JP7731156B2 (ja) | Ｄｎａが編集された真核細胞を製造する方法、および当該方法に用いられるキット | |
| JP7257062B2 (ja) | ゲノム編集方法 | |
| JP6700306B2 (ja) | 受精前の卵細胞、受精卵、及び標的遺伝子の改変方法 | |
| CN108291218B (zh) | 核酸酶非依赖性靶向基因编辑平台及其用途 | |
| KR102531016B1 (ko) | 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물 | |
| JP6815986B2 (ja) | 大型家畜の接合体における標的化ゲノム編集 | |
| JP7219972B2 (ja) | Ｄｎａ二本鎖切断に非依存的な標的化遺伝子編集プラットフォームおよびその用途 | |
| CN102625655B (zh) | 使用锌指核酸酶在大鼠中进行基因组编辑 | |
| JP7063885B2 (ja) | 標的にされた増大するｄｎａ脱メチル化 | |
| US20110023157A1 (en) | Equine genome editing with zinc finger nucleases | |
| US20150156996A1 (en) | Livestock with genetically modified prolactin receptor | |
| MX2014015204A (es) | Metodos y composiciones para generar alelos con inactivacion condicional. | |
| JPWO2008072540A1 (ja) | Ｔｏｌ１因子のトランスポザーゼ及びそれを用いたＤＮＡ導入システム | |
| CN108347908A (zh) | 具有增加的热耐受性的经遗传修饰的动物 | |
| JP2018531003A6 (ja) | 向上した耐暑性を有する遺伝子改変動物 | |
| US20040141994A1 (en) | Viral recombinases, related articles, and methods of use thereof | |
| JP2001523449A (ja) | レスポンダー表現型に関わる核酸およびその適用 | |
| Jin et al. | Haploid male germ cell‐and oocyte‐specific Mbd3l1 and Mbd3l2 genes are dispensable for early development, fertility, and zygotic DNA demethylation in the mouse | |
| Uh | Maintaining Proper Levels of DNA Methylation Marks Through the TET Family is Critical for Normal Embryo Development in Pigs | |
| EA040859B1 (ru) | Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе | |
| HK40021189B (zh) | Dna被编辑了的真核细胞的制造方法、和在该方法中使用的试剂盒 | |
| Yang | Expression and methylation patterns of imprinted genes in deceased newborn clones and surviving adult clones in cattle | |
| HK1258288B (en) | Nuclease-independent targeted gene editing platform and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100412 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100412 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121206 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130304 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130311 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130405 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130412 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130801 |